加载中
Solana Co. is a medical device firm specializing in neurotechnology, dedicated to improving neurological wellness. The company's strategy involves developing, licensing, and acquiring innovative, non-invasive platform technologies. These technologies are designed to enhance the brain's intrinsic capacity for self-healing and mitigate the effects of neurological diseases or trauma. A prime example of their work is the development of an investigational portable neuromodulation stimulator. This device uniquely delivers neurostimulation through the tongue. Clinical studies have indicated that this approach significantly enhances the efficacy of physical exercises for individuals experiencing neurological symptoms stemming from conditions like disease or trauma, including mild-to-moderate traumatic brain injury. Established on March 13, 2014, Solana Co. maintains its headquarters in Newtown, Pennsylvania.
前收盘价
US$2.39
US$0.00 · 0.00%
盘后
US$2.37
−US$0.02 · -0.84%
10月12日 19:38 ET
盘中时间采用ET。市场数据可能有所延迟。
Solana Co. is a medical device firm specializing in neurotechnology, dedicated to improving neurological wellness. The company's strategy involves developing, licensing, and acquiring innovative, non-invasive platform technologies. These technologies are designed to enhance the brain's intrinsic capacity for self-healing and mitigate the effects of neurological diseases or trauma. A prime example of their work is the development of an investigational portable neuromodulation stimulator. This device uniquely delivers neurostimulation through the tongue. Clinical studies have indicated that this approach significantly enhances the efficacy of physical exercises for individuals experiencing neurological symptoms stemming from conditions like disease or trauma, including mild-to-moderate traumatic brain injury. Established on March 13, 2014, Solana Co. maintains its headquarters in Newtown, Pennsylvania.
日内区间
当前US$2.39
52周区间
当前US$2.39
盘中时间采用ET。市场数据可能有所延迟。
Solana Co. is a medical device firm specializing in neurotechnology, dedicated to improving neurological wellness. The company's strategy involves developing, licensing, and acquiring innovative, non-invasive platform technologies. These technologies are designed to enhance the brain's intrinsic capacity for self-healing and mitigate the effects of neurological diseases or trauma. A prime example of their work is the development of an investigational portable neuromodulation stimulator. This device uniquely delivers neurostimulation through the tongue. Clinical studies have indicated that this approach significantly enhances the efficacy of physical exercises for individuals experiencing neurological symptoms stemming from conditions like disease or trauma, including mild-to-moderate traumatic brain injury. Established on March 13, 2014, Solana Co. maintains its headquarters in Newtown, Pennsylvania.
日内区间
当前US$2.39
52周区间
当前US$2.39
盈利能力占已公布营收的百分比。
营收
营业利润
净利润
| 项目（USD） | 2025财年 | 2024财年 | 2023财年 | 2022财年 | 2021财年 |
|---|---|---|---|---|---|
| 营收 | 601.7万 USD | 52万 USD | 64.4万 USD | 78.7万 USD | 52.2万 USD |
| 销货成本 | 50万 USD | 58.2万 USD | 58.3万 USD | 46.3万 USD | 29.8万 USD |
| 毛利 | 551.7万 USD | −6.2万 USD | 6.1万 USD | 32.4万 USD | 22.4万 USD |
| 研究与开发 | 351.1万 USD | 365.9万 USD | 294.2万 USD | 426.2万 USD | 599万 USD |
| 销售、一般及管理费用 | 2312.7万 USD | 1011.8万 USD | 927.1万 USD | 1064万 USD | 1217.6万 USD |
| 营业费用 | 2663.8万 USD | 1384.1万 USD | 1248.9万 USD | 1584万 USD | 1836.6万 USD |
| 利息收入 | — | — | 25.7万 USD | — | — |
| 利息支出 | 63.5万 USD | 1.7万 USD | — | 83.4万 USD | — |
| 折旧和摊销 | 68万 USD | 6万 USD | 16.2万 USD | 25.5万 USD | 31.2万 USD |
| 营业利润 | −2112.1万 USD | −1390.3万 USD | −1242.8万 USD | −1551.6万 USD | −1814.2万 USD |
| 净利润 | −4089万 USD | −1174.2万 USD | −885万 USD | −1407.2万 USD | −1813.2万 USD |
公司数据更新于 2026年10月13日。
近期已公布业绩
近期已公布业绩
第三方分析师预期可能变化，并非 GoAI 建议。
报告持有此股票敞口的交易所交易基金。
AI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
